Earnings News
Quarterly earnings reports, revenue surprises, and EPS results from top companies. Follow earnings season with analyst estimates and post-earnings stock moves.
Clorox's 5.2% Dividend Yield Attracts Despite Tight Earnings Cushion
Clorox (CLX) ended Friday at $96.32, yielding 5.15%, with the dividend consuming 88%-91% of adjusted EPS guidance. The next catalyst is August 3 earnings.
Lululemon's Market Cap Falls Behind Deckers as Growth Questions Mount
Lululemon's market capitalization trails Deckers by $1.93 billion, even though its midpoint sales are nearly double. The stock closed at $116.33, down 2.07% on Friday.
Disney Gains on Streaming Margin Focus After Netflix Slide
Disney shares advanced 2.1% last week as the market contrasted its streaming margin progress with Netflix's steeper decline. Comcast reports on July 23.
PepsiCo's Overseas Strength Offsets U.S. Weakness; Stock Flat
PepsiCo shares closed nearly flat as strong international performance, which contributed 209% of core operating-profit growth, balanced weaker North American results.
Goldman Sachs Ends Week Up 1% as Investors Focus on Revenue Sustainability
Goldman Sachs (GS) shares ended the week up 1.0% at $1,065.22, even as a 2.76% Friday drop brought the stock 7.5% below its record close, with investors weighing the durability of revenue from equities and FICC.
3M Stock Edges Up on Azure Deal; Q2 Earnings in Focus
3M shares gained 1.5% last week after Microsoft Azure selected its EBO connectors. Investors await Q2 earnings Tuesday, with consensus estimates of $2.27 EPS and $6.38B revenue.
Annaly's High Dividend Faces Scrutiny Ahead of Earnings
Annaly Capital Management's 13% forward yield is under pressure as Q2 earnings approach, with dividend coverage razor-thin and market rates rising.
Douglas Dynamics Rebounds on Margin Optimism
Shares of Douglas Dynamics (NYSE:PLOW) gained 3.7% last week, beating the Russell 2000 by 4.2 percentage points, as the market focuses on margin expansion prospects.
Iovance Biotherapeutics Soars 18% as Amtagvi Sales Target Nears
Iovance Biotherapeutics (IOVA) shares jumped 18% as investors focus on the upcoming sales test for Amtagvi, with second-quarter revenue guidance of $86-$88 million.
CSL Faces US$650M Revenue Headwinds Ahead of August Earnings Report
CSL Limited (ASX:CSL) disclosed three major revenue headwinds totaling US$650 million, representing 4.3% of FY26 forecast, as it prepares for its August 18 earnings report.
